TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-08-09
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
2858
Registration Number
NCT01178125
Locations
🇮🇱

Teva Investigational Site 80102, Tel-Aviv, Israel

🇮🇱

Teva Investigational Site 80101, Modi'in, Israel

🇮🇱

Teva Investigational Site 80106, Tel-Aviv, Israel

and more 59 locations

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

First Posted Date
2010-06-02
Last Posted Date
2012-05-23
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
474
Registration Number
NCT01134705
Locations
🇺🇸

Teva Clinical Study Site, Bellevue, Washington, United States

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

First Posted Date
2010-05-31
Last Posted Date
2012-07-04
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
107
Registration Number
NCT01133626
Locations
🇺🇸

Teva Clinical Study Site, San Antonio, Texas, United States

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

First Posted Date
2010-05-19
Last Posted Date
2023-03-28
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
381
Registration Number
NCT01126190
Locations
🇧🇬

Teva Investigational Site 3506, Sofia District, Bulgaria

🇧🇬

Teva Investigational Site 3503, Stara Zagora, Bulgaria

🇷🇴

Teva Investigational Site 4011, Cluj-Napoca, Romania

and more 56 locations

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-03-18
Last Posted Date
2016-05-23
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
43
Registration Number
NCT01088984
Locations
🇺🇸

Teva Investigational Site 15, New York, New York, United States

🇺🇸

Teva Investigational Site 17, Orange, California, United States

🇺🇸

Teva Investigational Site 12, San Diego, California, United States

and more 47 locations

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-03-11
Last Posted Date
2022-07-07
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
82
Registration Number
NCT01085084
Locations
🇺🇸

Teva Investigational Site 1366, Charleston, South Carolina, United States

🇺🇸

Teva Investigational Site 1369, Bronx, New York, United States

🇨🇦

Teva Investigational Site 1142, Montreal, Quebec, Canada

and more 19 locations

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

First Posted Date
2010-03-11
Last Posted Date
2022-03-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
46
Registration Number
NCT01085097
Locations
🇺🇸

Teva Investigational Site 1022, Lake Success, New York, United States

🇬🇧

Teva Investigational Site 3412, Dudley, United Kingdom

🇨🇦

Teva Investigational Site 1114, Winnipeg, Manitoba, Canada

and more 27 locations

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

First Posted Date
2010-02-11
Last Posted Date
2021-12-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
1404
Registration Number
NCT01067521
Locations
🇨🇿

Teva Investigational Site 5432, Prague 10, Czechia

🇺🇸

Teva Investigational Site 1326, Fullerton, California, United States

🇺🇸

Teva Investigational Site 1349, Columbus, Ohio, United States

and more 173 locations

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

First Posted Date
2010-01-29
Last Posted Date
2021-11-09
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
72
Registration Number
NCT01058863
Locations
🇺🇸

Teva Clinical Study Site, Portland, Oregon, United States

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

First Posted Date
2010-01-26
Last Posted Date
2022-02-02
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Target Recruit Count
47
Registration Number
NCT01056159
Locations
🇺🇸

Teva Clinical Study Site, Lake Oswego, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath